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Kathryn B. Garber1,*We Can Make It Better, Stronger, Faster.
The momentum is building for whole-exome and whole-
genome sequencing to be used routinely in a clinical
setting. One of the limitations is the time it takes to
complete the sequence and then to finish its analysis.
The faster the time to a result, the more quickly the diag-
nosis has the potential to be used to alter patient manage-
ment. Saunders et al. developed a strategy that allowed
them to go from blood sample to genome sequence to
diagnosis in 50 hr. To hasten the time to molecular diag-
nosis, they generated sequence by using Illumina’s HiSeq
platform and developed an automated-analysis strategy
that prioritized sequence variation on the basis of pre-
dicted functional consequence and candidate genes on
the basis of clinical phenotype. A retrospective analysis
proved that their pipeline could work because they were
able to confirm the molecular diagnosis of two patients
with rare disorders. In a prospective analysis of patients
in a neonatal intensive-care unit, they uncovered a defin-
itive or likely molecular diagnosis in three out of four
families affected by a range of phenotypes from a severe
erosive dermatitis to a neonatal epilepsy syndrome.
Keeping in mind that they were testing children, they
focused their automated analysis on the genetic variation
most likely to be relevant to the diagnosis and were
thereby able to mask incidental findings in each genome.
Although this approach has been tested on a limited
number of patients so far, it does show that it is possible
to achieve a diagnosis via whole-genome sequencing
faster than ever before.
Saunders et al. (2012). Sci. Transl. Med. 4, 154ra135.
Exome Studies Have a High Rate of Success
in ID-Affected Individuals
A significant portion of individuals with intellectual
disability (ID) have a chromosome abnormality or Fragile
X syndrome. Even so, the majority lack a specific genetic
diagnosis. Beyond a chromosome microarray and Fragile
X testing, one can use clinical features to suggest single-
gene causes of ID, but because there are hundreds of rele-
vant genes, identifying a manageable number of candidate
genes to be sequenced is no easy task. Two recent papers
attempted to circumvent the gene-by-gene approach
through the use of exome sequencing to identify the1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Americanetiology of severe ID. Both found that they could explain
just as many—if not more—ID cases as they could with
chromosome microarray, which is a currently recommen-
ded first-tier genetic test for ID. De novo, dominant muta-
tions are the main contributor to the pathogenic sequence
variation found in these samples. In contrast, autosomal-
recessive mutations appear unlikely to play a major role
in outbred populations affected by ID. Besides being
cheaper and faster than wading through one ID-associated
gene at a time, the exome-based approach can also identify
pathogenic mutations in individuals who have atypical
clinical presentations and who would thus be missed by
the phenotype-based prioritization of candidate genes.
de Ligt et al. (2012). N. Engl. J. Med. Published online
October 3, 2012. http://dx.doi.org/10.1056/NEJMoa1206524.
Rauch et al. (2012). Lancet. Published online September 27,
2012. http://dx.doi.org/10.1016/S0140-6736(12)61480-9.
The BPA-free Movement
I’m sure many of you are aware of the movement toward
going ‘‘BPA-free’’ given that many water bottles and other
containers declare their status in bold type. BPA is bisphe-
nol-A, a compound that is used in making certain plastics
and that is widely found in many products. Rodent models
of BPA exposure suggest that this endocrine-disrupting
chemical has detrimental effects on meiosis during oogen-
esis. Rodents are one thing, but what about a model that is
more similar to humans? To get one step closer, Hunt et al.
assessed the reproductive effects of BPA exposure on rhesus
macaques. Similar to what has been found in rodents, BPA
exposure during fetal development leads to increases in
crossover events between chromosomes, as well as disrup-
tion of follicle formation. BPA exposure increases the num-
ber of follicles containing multiple oocytes, and this has
previously beenassociatedwith adiminishedquality of eggs.
Hunt et al. (2012). Proc. Natl. Acad. Sci. USA. Published
online September 24, 2012. http://dx.doi.org/10.1073/pnas.
1207854109.
2pq
When one is asked to provide carrier frequencies for auto-
somal-recessive conditions, Hardy-Weinberg equilibrium
might jump to mind because it provides a way to make
the calculation on the basis of the incidence of disease.ta, GA 30322, USA
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Carrier-frequency estimates are crucial determinants of
recommended carrier screens, which have, thus far, largely
been restricted to particular racial and ethnic populations.
Some examples are sickle cell disease screening in African
Americans and Tay-Sachs disease screening in the Ashke-
nazi Jewish population. Lazarin et al. recently presented
more accurate carrier-frequency estimates based on empir-
ical data from a diverse population of more than 23,000
individuals who each received testing for more than
100 conditions (via Counsyl’s Universal Genetic Test).
Although for many conditions carrier frequencies did not
differ substantially from previous estimates, there were
some notable exceptions, including the fact that carriers
for carnitine palmitoyltransferase II deficiency and
Smith-Lemli-Opitz syndrome were much more common
than expected in certain populations. The data also high-
light for each condition the fraction of carriers who do
not belong to the racial or ethnic group targeted by current
screening recommendations—this fraction is as high as
50%. The authors use these results to argue for panethnic
screening. One consideration, though, is the increased
burden for genetic counseling as carrier screening expands.
Overall, 24% of individuals tested in this study were
a carrier for at least one severe recessive disease. This isn’t
unexpected, but we will need to find ways to manage the
large number of people who will need further testing and
counseling on the basis of their results.
Lazarin et al. (2012). Genet. Med. Published online
September 13, 2012. http://dx.doi.org/10/1038/gim.2012.114.770 The American Journal of Human Genetics 91, 769–770, NovembArbaclofen Trial for Fragile X
Individuals with Fragile X syndrome (FXS) tend to be on
several medications. Each is meant to control one of the
disorder’s various features, such as anxiety, hyperactivity,
and aggression. Basic research over the past few years
has provided a better understanding of the underlying
pathophysiology of this disorder, giving hope that treat-
ments targeting the molecular defect might engender
more global improvements in individuals affected by
FXS. Dysregulated neuronal signaling is believed to be
central to FXS. The GABAB agonist STX209, or arbaclofen,
targets this signaling and rescues some aspects of the
phenotype in Fmr1-knockout mice. Two recent papers
further explored the effects of STX209 in a mouse model
of FXS and in a clinical trial. Henderson et al. found that
STX209 corrected two of the key pathologies in Fmr1-
knockout mice: increased mRNA translation in the
cortex and increased spine density in the dendrites. In
the clinical trial, Berry-Kravis et al. found that although
STX209 did not yield improvements in the main outcome
measure of irritability and aggression, there were improve-
ments in parent-nominated problem behaviors. A posthoc
analysis using a newly developed assessment tool for FXS
found improvements in social avoidance, particularly in
the subgroup that started with the most severe social
impairments.
Henderson et al. (2012). Sci. Transl. Med. 4, 152ra128.
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